Cargando…

High-Throughput Screening of the ReFRAME Library Identifies Potential Drug Repurposing Candidates for Trypanosoma cruzi

Chagas disease, caused by the kinetoplastid parasite Trypanosoma cruzi, affects between 6 and 7 million people worldwide, with an estimated 300,000 to 1 million of these cases in the United States. In the chronic phase of infection, T. cruzi can cause severe gastrointestinal and cardiac disease, whi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bernatchez, Jean A., Chen, Emily, Hull, Mitchell V., McNamara, Case W., McKerrow, James H., Siqueira-Neto, Jair L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7232187/ https://www.ncbi.nlm.nih.gov/pubmed/32224991 http://dx.doi.org/10.3390/microorganisms8040472

Ejemplares similares

The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis
por: Janes, Jeff, et al.
Publicado: (2018)

Identification of Leucinostatins from Ophiocordyceps sp. as Antiparasitic Agents against Trypanosoma cruzi
por: Bernatchez, Jean A., et al.
Publicado: (2022)

Long term follow-up of Trypanosoma cruzi infection and Chagas disease manifestations in mice treated with benznidazole or posaconazole
por: Calvet, Claudia Magalhães, et al.
Publicado: (2020)

Cysteine Protease Inhibitors Cure an Experimental Trypanosoma cruzi Infection
por: Engel, Juan C., et al.
Publicado: (1998)

Machine Learning Models and Pathway Genome Data Base for Trypanosoma cruzi Drug Discovery
por: Ekins, Sean, et al.
Publicado: (2015)

The Trypanosoma cruzi Protease Cruzain Mediates Immune Evasion
por: Doyle, Patricia S., et al.
Publicado: (2011)

Binding Mode and Potency of N-Indolyloxopyridinyl-4-aminopropanyl-Based Inhibitors Targeting Trypanosoma cruzi CYP51
por: Vieira, Debora F., et al.
Publicado: (2014)

Screening the CALIBR ReFRAME Library in Search for Inhibitors of Candida auris Biofilm Formation
por: Wall, Gina, et al.
Publicado: (2020)

Phenotypic screening of the ReFRAME drug repurposing library to discover new drugs for treating sickle cell disease
por: Metaferia, Belhu, et al.
Publicado: (2022)

Structural Characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei Bound to the Antifungal Drugs Posaconazole and Fluconazole
por: Chen, Chiung-Kuang, et al.
Publicado: (2010)

In Vitro and In Vivo Studies of the Trypanocidal Properties of WRR-483 against Trypanosoma cruzi
por: Chen, Yen Ting, et al.
Publicado: (2010)

4-Aminopyridyl-Based CYP51 Inhibitors as Anti-Trypanosoma cruzi Drug Leads with Improved Pharmacokinetic Profile and in Vivo Potency
por: Calvet, Claudia M., et al.
Publicado: (2014)

Repurposing of terconazole as an anti Trypanosoma cruzi agent
por: Reigada, Chantal, et al.
Publicado: (2019)

Location, Location, Location: Five Facts about Tissue Tropism and Pathogenesis
por: McCall, Laura-Isobel, et al.
Publicado: (2016)

An Image-Based Algorithm for Precise and Accurate High Throughput Assessment of Drug Activity against the Human Parasite Trypanosoma cruzi
por: Moon, Seunghyun, et al.
Publicado: (2014)

Trypanosoma cruzi CYP51 Inhibitor Derived from a Mycobacterium tuberculosis Screen Hit
por: Chen, Chiung-Kuang, et al.
Publicado: (2009)

Diverse Inhibitor Chemotypes Targeting Trypanosoma cruzi CYP51
por: Gunatilleke, Shamila S., et al.
Publicado: (2012)

High-throughput screening of the ReFRAME, Pandemic Box, and COVID Box drug repurposing libraries against SARS-CoV-2 nsp15 endoribonuclease to identify small-molecule inhibitors of viral activity
por: Choi, Ryan, et al.
Publicado: (2021)

Identification of Trypanosoma cruzi Polyamine Transport Inhibitors by Computational Drug Repurposing
por: Reigada, Chantal, et al.
Publicado: (2019)

4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection
por: Calvet, Claudia Magalhaes, et al.
Publicado: (2017)

High Throughput and Computational Repurposing for Neglected Diseases
por: Hernandez, Helen W., et al.
Publicado: (2018)

Genome-scale metabolic models highlight stage-specific differences in essential metabolic pathways in Trypanosoma cruzi
por: Shiratsubaki, Isabel S., et al.
Publicado: (2020)

Repurposing of rabeprazole as an anti-Trypanosoma cruzi drug that targets cellular triosephosphate isomerase
por: García-Torres, Itzhel, et al.
Publicado: (2023)

High Throughput Selection of Effective Serodiagnostics for Trypanosoma cruzi infection
por: Cooley, Gretchen, et al.
Publicado: (2008)

High Throughput Screening for Anti–Trypanosoma cruzi Drug Discovery
por: Alonso-Padilla, Julio, et al.
Publicado: (2014)

Heat shock protein 90 inhibitors repurposed against Entamoeba histolytica
por: Shahinas, Dea, et al.
Publicado: (2015)

Spatial metabolomics identifies localized chemical changes in heart tissue during chronic cardiac Chagas Disease
por: Dean, Danya A., et al.
Publicado: (2021)

A high-throughput cloning system for reverse genetics in Trypanosoma cruzi
por: Batista, Michel, et al.
Publicado: (2010)

In vitro anti-Trypanosoma cruzi activity enhancement of curcumin by its monoketone tetramethoxy analog diveratralacetone
por: Souza, Julia M., et al.
Publicado: (2021)

Comics and critical librarianship: reframing the narrative in academic libraries
por: Piepmeier, Olivia, et al.
Publicado: (2019)

In Vitro and In Vivo High-Throughput Assays for the Testing of Anti-Trypanosoma cruzi Compounds
por: Canavaci, Adriana M. C., et al.
Publicado: (2010)

Drug Discovery for Schistosomiasis: Hit and Lead Compounds Identified in a Library of Known Drugs by Medium-Throughput Phenotypic Screening
por: Abdulla, Maha-Hamadien, et al.
Publicado: (2009)

Library of Selenocyanate and Diselenide Derivatives as In Vivo Antichagasic Compounds Targeting Trypanosoma cruzi Mitochondrion
por: Martín-Escolano, Rubén, et al.
Publicado: (2021)

Repurposing Carvedilol as a Novel Inhibitor of the Trypanosoma cruzi Autophagy Flux That Affects Parasite Replication and Survival
por: Rivero, Cynthia Vanesa, et al.
Publicado: (2021)

Dysregulation of Glycerophosphocholines in the Cutaneous Lesion Caused by Leishmania major in Experimental Murine Models
por: Parab, Adwaita R., et al.
Publicado: (2021)

Molecular dissection of Chagas induced cardiomyopathy reveals central disease associated and druggable signaling pathways
por: Wozniak, Jacob M., et al.
Publicado: (2020)

A systematic review of the diagnostic aspects and use of Trypanosoma rangeli as an immunogen for Trypanosoma cruzi infection
por: Bayão, Taciana de Souza, et al.
Publicado: (2020)

Current understanding of the Trypanosoma cruzi-cardiomyocyte interaction
por: Calvet, Claudia M., et al.
Publicado: (2012)

Drug repurposing for Chagas disease: In vitro assessment of nimesulide against Trypanosoma cruzi and insights on its mechanisms of action
por: Trindade, Joana D’Arc S., et al.
Publicado: (2021)

Kinetic and Structural Characterization of Trypanosoma cruzi Hypoxanthine–Guanine–Xanthine Phosphoribosyltransferases and Repurposing of Transition-State Analogue Inhibitors
por: Glockzin, Kayla, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8mun0vm6eisnqrhobiomrj6igh